CO4750673A1 - Derivados solubles compuestos de polipeptidos solubles y elementos que se unen a membrana - Google Patents

Derivados solubles compuestos de polipeptidos solubles y elementos que se unen a membrana

Info

Publication number
CO4750673A1
CO4750673A1 CO97039907A CO97039907A CO4750673A1 CO 4750673 A1 CO4750673 A1 CO 4750673A1 CO 97039907 A CO97039907 A CO 97039907A CO 97039907 A CO97039907 A CO 97039907A CO 4750673 A1 CO4750673 A1 CO 4750673A1
Authority
CO
Colombia
Prior art keywords
membrane
polypeptide
elements
group
derivative
Prior art date
Application number
CO97039907A
Other languages
English (en)
Inventor
Smith Richard Anthony Godwin
Ian Dodd
Ewa Irena Mossakowska Danuta
Original Assignee
Adprotech Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adprotech Plc filed Critical Adprotech Plc
Publication of CO4750673A1 publication Critical patent/CO4750673A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un derivado soluble de un polipéptido soluble, (P)comprendiendo dicho derivado dos o más elementos heterológos que se unen a la membrana con baja afinidad hacia la membrana(W,X) asociados covalentemente con el polipéptido, donde dichos elementos son capaces de interaccionar, independientemente y con aditividad termodinámica, con componentes de membranas celulares o artificiales expuestas a fluidos extracelulares y donde todos los mencionados dos o más elementos exhiben baja afinidad hacia la membrana.2Un procedimiento para preparar un derivado según la reivindicación 1, procedimiento que comprende expresar ADN que codifica la porción polipeptídica de dicho derivado en una célula hospedadora recombinante y recuperar el producto y, después de esto, modificar después de la traducción el polipéptido para introducir químicamente elementos que se unen a la membrana. 3Un elemento peptídico que se une a la membrana con baja afinidad hacia la membrana, que comprende una o más modificaciones seleccionadas entre: un resto de cisteína terminal, opcionalmente activado en el grupo tiol; un grupo N-haloacetilo (en que halo significa cloro, bromo o yodo) localizado en el extremo N terminal del péptido o en un grupo e-amino de un resto de lisina; un grupo amido en el extremo C terminal; un grupo bloqueante N terminal; y un grupo N-acilo de ácido graso en el extremo N terminal o en un grupo e-amino de un resto de lisina, para la manufactura de un derivado polipéptido de acuerdo con la Reivindicación 1.
CO97039907A 1996-07-15 1997-07-15 Derivados solubles compuestos de polipeptidos solubles y elementos que se unen a membrana CO4750673A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9614871.3A GB9614871D0 (en) 1996-07-15 1996-07-15 Compounds

Publications (1)

Publication Number Publication Date
CO4750673A1 true CO4750673A1 (es) 1999-03-31

Family

ID=10796956

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97039907A CO4750673A1 (es) 1996-07-15 1997-07-15 Derivados solubles compuestos de polipeptidos solubles y elementos que se unen a membrana

Country Status (17)

Country Link
US (3) US6713606B1 (es)
EP (1) EP0912730B1 (es)
JP (1) JP4177457B2 (es)
AR (1) AR007737A1 (es)
AT (1) ATE419345T1 (es)
AU (1) AU732725B2 (es)
CA (1) CA2260288A1 (es)
CO (1) CO4750673A1 (es)
DE (1) DE69739186D1 (es)
DK (1) DK0912730T3 (es)
ES (1) ES2321245T3 (es)
GB (1) GB9614871D0 (es)
IL (3) IL128034A0 (es)
NZ (1) NZ333722A (es)
TW (1) TW538048B (es)
WO (1) WO1998002454A2 (es)
ZA (1) ZA976216B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9704519D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Compounds
IL136230A0 (en) 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
EP0953576B1 (en) 1998-04-30 2005-11-02 Curis, Inc. Active hedgehog protein conjugate, process for its production and use
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
GB0016811D0 (en) * 2000-07-07 2000-08-30 Adprotech Ltd Lipid rafts
GB0026924D0 (en) 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
GB0117193D0 (en) * 2001-07-13 2001-09-05 Adprotech Ltd Protein modification reagents
GB0123262D0 (en) * 2001-09-27 2001-11-21 Adprotech Ltd Polymeric compounds
GB0220936D0 (en) 2002-09-05 2002-10-23 Adprotech Ltd Modified therapeutic agents
FR2854897B1 (fr) * 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
US7858108B2 (en) * 2003-10-21 2010-12-28 Richard Nagler Elutable surface coating
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US8124097B2 (en) * 2004-01-21 2012-02-28 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
WO2005115430A1 (en) 2004-05-27 2005-12-08 Gropep Limited Treatment of inflammatory airway disease
JP2009508937A (ja) * 2005-09-22 2009-03-05 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Ｔ細胞免疫を調節するためのジアステレオマーペプチド
JP2009529530A (ja) 2006-03-09 2009-08-20 インフラザイム・ファーマシューティカルズ・リミテッド 新規の抗生物質組成物
EP2083841B1 (en) 2006-10-20 2013-11-20 Celldex Therapeutics, Inc. SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) PROTEIN FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE
EP2134373A4 (en) * 2007-02-28 2014-04-02 Yeda Res & Dev CORE TARGETING SEQUENCES
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CA2751673A1 (en) * 2009-02-20 2010-08-26 Ipsen Pharma S.A.S Analogues of neuropeptide y having proline substitution at position 34
EP2419119B1 (en) * 2009-04-16 2017-06-07 Ruprecht-Karls-Universität Heidelberg Muscle function enhancing peptide
GB0915519D0 (en) 2009-09-04 2009-10-07 King S College London Ntithrombotic compounds
WO2011050334A1 (en) * 2009-10-22 2011-04-28 Yong Zhu Compositions and methods for re-programming cells without genetic modification for treatment of obesity and related diseases
US9295713B2 (en) 2010-09-15 2016-03-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
EP2632476B1 (en) 2010-10-27 2017-06-14 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
GB201402267D0 (en) 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN110240656A (zh) * 2019-04-24 2019-09-17 中山大学附属第三医院 一种融合蛋白及其制备方法与应用
CN110551177A (zh) * 2019-08-29 2019-12-10 安徽瑞达健康产业有限公司 多肽、多肽衍生物、多肽-抗体复合物及制备、应用
GB201913804D0 (en) 2019-09-25 2019-11-06 Prostate Cancer Res Centre Fusion polypeptides
WO2024092160A2 (en) * 2022-10-26 2024-05-02 Flagship Pioneering Innovations Vii, Llc Bifunctional proteases and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536391A (en) 1982-11-17 1985-08-20 Otsuka Pharmaceutical Co. Process for preparing urokinase complex
EP0114787B1 (de) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
GB8334498D0 (en) 1983-12-24 1984-02-01 Beecham Group Plc Compounds
GB8400653D0 (en) 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
GR860875B (en) 1985-04-04 1986-07-29 Beecham Group Plc Novel compounds
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
JP2573007B2 (ja) * 1987-12-28 1997-01-16 株式会社成和化成 修飾された動物毛粉末
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5326700A (en) 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
DE69328098T2 (de) * 1992-06-24 2000-08-24 Adprotech Plc Lösliche derivate des complement type-rezeptors (cr1)
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
PT730608E (pt) * 1993-05-17 2002-09-30 Avant Immunotherapeutics Inc Composicoes compreendendo hidratos de carbono e proeinas relacionadas pelo complemento e metodos para produzir e utilizar as referidas composicoes
WO1995023512A1 (en) * 1994-03-03 1995-09-08 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US5776689A (en) 1996-07-19 1998-07-07 The Regents Of The University Of California Protein recruitment system
WO2000020867A1 (en) 1998-10-01 2000-04-13 Alexey Vladimirovich Titievsky A novel ret-independent signaling pathway for gdnf
GB0220936D0 (en) * 2002-09-05 2002-10-23 Adprotech Ltd Modified therapeutic agents

Also Published As

Publication number Publication date
IL128034A0 (en) 1999-11-30
DE69739186D1 (de) 2009-02-12
US6713606B1 (en) 2004-03-30
US7655617B2 (en) 2010-02-02
EP0912730A2 (en) 1999-05-06
IL166051A0 (en) 2006-01-15
DK0912730T3 (da) 2009-04-27
AR007737A1 (es) 1999-11-10
ES2321245T3 (es) 2009-06-03
GB9614871D0 (en) 1996-09-04
US20040266684A1 (en) 2004-12-30
AU3693997A (en) 1998-02-09
WO1998002454A3 (en) 1998-04-02
ATE419345T1 (de) 2009-01-15
IL128034A (en) 2007-03-08
TW538048B (en) 2003-06-21
CA2260288A1 (en) 1998-01-22
JP4177457B2 (ja) 2008-11-05
AU732725B2 (en) 2001-04-26
ZA976216B (en) 1999-04-14
US20100286367A1 (en) 2010-11-11
WO1998002454A2 (en) 1998-01-22
JP2000515370A (ja) 2000-11-21
NZ333722A (en) 2000-09-29
EP0912730B1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
CO4750673A1 (es) Derivados solubles compuestos de polipeptidos solubles y elementos que se unen a membrana
Press et al. The N-and c-terminal amino acid sequences of the heavy chain from a pathological human immunoglobulin IgG
Bailey et al. Partial characterization of a second basement membrane collagen in human placenta: evidence for the existence of two type IV collagen molecules
Maghuin‐Rogister et al. Luteinizing Hormone: The Primary Structures of the β‐Subunit from Bovine and Porcine Species
SE8904087L (sv) Peptide derivates
YU71800A (sh) Hibridni polipeptidi sa pojačanim farmakokinetičkim osobinama
IT1203672B (it) Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
AR247590A1 (es) Una secuencia de adn que codifica derivados de factor viii humano recombinante y un procedimiento para su obtencion
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
ES2149149T1 (es) Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
DE69129803D1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
DE69731097D1 (de) Conotoxin peptid pviia
Buchanan A cystine-rich protein fraction from oxidized alpha-keratin.
DE68927379D1 (de) Plättchen blockierende peptide
ES543938A0 (es) Un procedimiento para preparar un gen fusionado que codifica una proteina hibrida susceptible de marcado y empleo en diagnosis.
BRODIN et al. Characterization of two substance P antisera
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
Fawell et al. Androgen-regulated proteins of rat seminal vesicle secretion constitute a structurally related family present in the copulatory plug
Varadi et al. . beta.(Leu121-Lys122) segment of fibrinogen is in a region essential for plasminogen binding by fibrin fragment E
Okamoto et al. Semisynthesis of a Post‐Translationally Modified Protein by Using Chemical Cleavage and Activation of an Expressed Fusion Polypeptide
Takahashi et al. Isolation and Characterization of Multiple. Components of Basic Gonadotropin from Bullfrog (Rana catesbeiana) Pituitary Gland
Fasciotto et al. Processing of chromogranin A in the parathyroid: generation of parastatin-related peptides
SCHWARTZ et al. [12‐ASPARAGINE‐B] HUMAN INSULIN: An Analogue with Modification in the Hydrophobic Core of Insulin
DK1012162T3 (da) Opløselige proteiner